Yeah, I think that it does seem that this marker is a predictive marker. The subtypes are predictive for response to radiation. So one simple way to think about it is if you’re in the good prognosis subtype, you may be treated effectively with lower doses of radiation therapy combined with chemotherapy, even for aggressive appearing tumors based on stage or infiltration...
Yeah, I think that it does seem that this marker is a predictive marker. The subtypes are predictive for response to radiation. So one simple way to think about it is if you’re in the good prognosis subtype, you may be treated effectively with lower doses of radiation therapy combined with chemotherapy, even for aggressive appearing tumors based on stage or infiltration. But if you’re in the high-risk subgroup, then I think other treatments are what we need to explore. We mentioned activating NF-kappa B to sensitize those tumors to radiation, but there’s also a lot of other options for those tumor subtypes as well that they may need to have a better cure rate, including new emerging immune therapies, possibly dual-specificity antibodies, and even CAR T’s.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
